Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/30504
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKim, SW-
dc.contributor.authorAlacevich, C-
dc.contributor.authorNicodemo, C-
dc.contributor.authorWittenberg, R-
dc.contributor.authorde Lusignan, S-
dc.contributor.authorPetrou, S-
dc.date.accessioned2025-01-18T13:42:35Z-
dc.date.available2025-01-18T13:42:35Z-
dc.date.issued2024-11-28-
dc.identifierORCiD: Sung Wook Kim https://orcid.org/0000-0002-1254-5038-
dc.identifierORCiD: Catia Nicodemo https://orcid.org/0000-0001-5490-9576-
dc.identifier.citationKim, S.W. et al. (2024) 'The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey', PharmacoEconomics - Open, 0 (ahead of print), pp. 1 - 15. doi: 10.1007/s41669-024-00544-0.en_US
dc.identifier.issn2509-4262-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/30504-
dc.descriptionData Availability Statement: These data were obtained from EMIS Health’s COVID-19 Symptom Surveillance tool. Accessing these data requires permission from EMIS Health as it is not publicly available.en_US
dc.descriptionCode Availability: The Stata code used for this study is available upon request.-
dc.description.abstractIntroduction: In the absence of a vaccination programme, the coronavirus disease 2019 (COVID-19) pandemic had substantial impacts on population health and wellbeing and health care services. We explored the association between COVID-19 status, sociodemographic, socioeconomic and clinical factors and economic costs during the second wave of the COVID-19 pandemic. Data: The study used patient-reported digital survey and symptom surveillance data collected between July and December 2020, in collaboration with a primary care computerised medical record system supplier, EMIS Health, in the UK. The study included 11,534 participants. Methods: Generalised linear models (GLM) and two-part regression models were used to estimate factors associated with economic costs (£sterling, 2022 prices) estimated from two perspectives: (i) a UK National Health Service (NHS) and personal social services (PSS) perspective and (ii) a societal perspective. Results: Experience of the onset of COVID-19 symptoms started more than 3 months ago was associated with significantly higher NHS and PSS costs (GLM: £319.8, two-part: £171.7) (p < 0.001) and societal costs (GLM: £776.9, two-part: £675.6) (p < 0.001) in both models. A positive test result within the previous 14 days was associated with significantly higher NHS and PSS costs (two-part: £389.1) (p < 0.05) and societal costs (GLM: £470.7, two-part: £439.2) (p < 0.01). Age between 31 and 55 years was associated with significantly higher societal costs than age between 16 and 30 years. Conclusion: This study identifies and quantifies factors associated with the economic costs incurred during the second wave of the COVID-19 pandemic in the UK. The results of our study can inform cross-country comparisons and other cost comparisons.en_US
dc.description.sponsorshipThis study was supported by a grant from the National Institute of Health Research (NIHR) School of Primary Care Research (SPCR) round 5-IV (Grant reference no: 620). Prof. Petrou receives support as a NIHR Senior Investigator (NF-SI-0616-10103) and from the NIHR Applied Research Collaboration Oxford and Thames Valley at the Oxford Health NHS Foundation Trust. Nicodemo receives support from the European Union. The PCR-4-ALL project has received funding under the Horizon Europe research and innovation programme (Grant agreement no. 101095606) and from Thames Valley at the Oxford Health NHS Foundation Trust.en_US
dc.format.extent1 - 15-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherAdis part of Springer Nature)en_US
dc.rightsAttribution-NonCommercial 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/-
dc.titleThe Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Surveyen_US
dc.typeArticleen_US
dc.date.dateAccepted2024-11-06-
dc.identifier.doihttps://doi.org/10.1007/s41669-024-00544-0-
dc.relation.isPartOfPharmacoEconomics - Open-
pubs.issueahead of print-
pubs.publication-statusPublished-
pubs.volume0-
dc.identifier.eissn2509-4254-
dc.rights.licensehttps://creativecommons.org/licenses/by-nc/4.0/legalcode.en-
dc.rights.holderThe Author(s)-
Appears in Collections:Brunel Business School Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2024. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc/4.0/.925.11 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons